API Development Services
API Development Services for AI-Integrated Drug Discovery & Global Commercial Supply
At PI Health Sciences, our API development services cover the full scientific and technical lifecycle – converting molecules into high-grade Active Pharmaceutical Ingredients for clinical and commercial use. We build scalable, robust, cGMP-compliant manufacturing processes that ensure consistent safety, quality, and efficacy at every stage, from early discovery through global launch.
Strategic route selection
Synthetic pathways evaluated for cost efficiency, safety profile, and scale-up potential.
Process optimization
Rigorous refinement of manufacturing sequences — impurity management and advanced analytical methods.
Scale-up & tech transfer
Systematic transition from lab-scale to pilot plant and full-scale, preserving product integrity throughout.
Commercial supply
Global manufacturing readiness with regulatory adherence across international markets.
Our API services include technology transfer, regulatory guidance, and manufacturing readiness. By embedding Chemistry, Manufacturing, and Controls (CMC) priorities into the entire development lifecycle, PI Health Sciences ensures a smooth progression from early-stage research to global commercial supply, providing reliable performance and regulatory adherence in international markets.
Discovery Process Chemistry
Where discovery meets development
We deliver in-silico discovery as a decision-support discipline embedded within early drug discovery chemistry. Our work focuses on the computational evaluation, prioritization, and risk assessment of chemical matter from hit generation through hit-to-lead optimization, helping teams focus chemistry on the most viable molecular directions. In-silico methods are applied as a filtering and prioritization layer, working alongside experimental validation to reduce uncertainty rather than introduce false confidence.
How Our Approach Is Different
Our approach goes beyond route replication to create processes that are designed for future scaleup and manufacturing success. By combining advanced route scouting, process optimization, impurity understanding, and early stage safety assessments, we build scalable and reproducible processes that reduce development risk and support seamless progression through subsequent development phases.
Core Design Principles
- Advanced route scouting using retrosynthetic analysis and parallel screening to identify next generation, scalable synthetic routes
- Rapid kilogram scale-up enabling seamless transition from milligram quantities to multikilogram batches for preclinical and toxicology supply
- Flow chemistry expertise applied for efficient execution of complex transformations
- Early impurity mapping through identification, synthesis, and characterization of process related impurities
- Integrated hazard evaluation using DSC and RC1 screening to ensure thermal stability and safe scaleup
Talk to Our Experts
Route Scouting
Accelerating Smarter Pathways to Development Success
Route scouting is the foundation of efficient process development, enabling the identification of synthetic pathways that are scalable, cost-effective, and commercially viable. At PI Health Sciences, we combine deep scientific expertise to rapidly evaluate, optimize, and validate synthetic routes for complex molecules. This integrated approach helps accelerate development timelines while supporting long-term manufacturing success.
How Our Approach Is Different
Our route scouting strategy combines the predictive power of artificial intelligence with the practical insights of experienced process chemists. By leveraging advanced retrosynthetic analysis, digital reaction optimization, and data-driven decision making, we identify promising pathways faster and with greater confidence. These digitally generated routes are then refined and validated by our scientific teams, ensuring they are not only innovative but also scalable, sustainable, and ready for downstream development.
Core Design Principles
- Data-driven decisions that accelerate development timelines.
- Scalable pathways optimized for future manufacturing success.
- Early risk identification to improve process robustness.
- Early identification and mitigation of chemical liabilities
- Sustainable chemistry principles embedded from the outset.
- Integrated digital and laboratory validation for confident execution.
Talk to Our Experts
Process Development
Designing Process For Safety,Quality And Effectiveness
At PI Health Sciences, process safety is treated as a critical foundation of pharmaceutical development, ensuring that every chemical process is thoroughly evaluated before advancing to large-scale manufacturing. Our commitment to delivering safe, effective, and high quality pharmaceutical products is reinforced through systematic safety assessments that are integrated into the development lifecycle from early stages through scaleup readiness.
How Our Approach Is Different
Our process safety approach is built on proactive evaluation rather than reactive control. Using a dedicated Process Safety Testing Laboratory equipped with advanced analytical and hazard assessment tools, we generate critical safety data across raw materials, intermediates, reaction mixtures, and drug substances. This enables early identification of potential risks and supports informed decision making before scaleup. By embedding safety considerations into process development, we ensure that appropriate engineering controls and mitigation strategies are established well in advance of manufacturing.
Core Design Principles
- Comprehensive hazard identification and risk assessment across all process stages
- Evaluation of thermal stability of raw materials, intermediates, and reaction systems
- Assessment of dust explosion and reactivity properties of compounds
- Generation of process safety information to support pre-scaleup decision making
- Development of Process Hazard Analysis (PHA) prior to manufacturing scale-up
- Implementation of engineering controls based on safety evaluation outcomes
- Integration of industry standard safety practices into all development activities
Talk to Our Experts
Process Safety & Engineering Excellence
Engineering Safe And Scalable Process
Process Safety & Engineering Excellence at PI Health Sciences provides the foundational framework that ensures safe, scalable, and compliant execution of chemical processes across development and manufacturing. By integrating process safety principles with advanced engineering design, we enable controlled scale-up of complex chemistries while maintaining consistent quality and regulatory compliance.
How Our Approach Is Different
Our approach integrates process safety and engineering directly into process development rather than treating them as downstream checks. Through early hazard identification, thermal risk evaluation, and engineering design inputs, we ensure that safety considerations actively shape process decisions. This enables inherently safer, more robust, and scalable processes that are aligned with both development timelines and commercial manufacturing requirements.
Core Design Principles
- Safety integrated from the earliest stages of process design
- Hazard identification and risk analysis embedded across development scales
- Inherently safer process design through substitution and minimization strategies
- Thermal and reaction risk evaluated using RC1 and DSC studies
- Scalable engineering design aligned with GMP manufacturing requirements
- Process intensification enabled through controlled and continuous processing strategies
- Containment focused design for high-potency and hazardous compounds
- Regulatory and environmental compliance built into engineering systems
Talk to Our Experts
Pre GMP Scale Up
Bridging the Gap Between Laboratory Development and Clinical Supply
Pre GMP Scale Up at PI Health Sciences focuses on enabling rapid, reliable, and cost efficient transition from discovery scale chemistry to multi kilogram production required for IND-enabling studies and early clinical development. Our non GMP scaleup services are designed to deliver high quality material for toxicology, process validation, and early regulatory submissions while minimizing development risk and timeline delays.
How Our Approach Is Different
Our approach emphasizes early process understanding and scale up de risking before entering full GMP manufacturing. By evaluating process safety, impurity formation, and operational constraints at kilo scale, we ensure that potential scale up challenges are identified and resolved early. This allows smoother transition into GMP campaigns with improved reproducibility, reduced risk, and faster clinical readiness.We align route selection, process optimization, and analytical support into a single workflow, ensuring that every batch generated contributes directly to IND-enabling requirements and future manufacturing readiness.
Core Design Principles
- Rapid delivery of non GMP material for IND-enabling and toxicology studies
- Early identification of scaleup risks including exotherms, mixing, and impurity formation
- Process optimization focused on yield, safety, and reproducibility
- Seamless scale transition from gram to multi kilogram quantities
- Integrated analytical characterization and impurity profiling
- Phase appropriate development aligned with USFDA and EMA expectations
- Tech transfer readiness built into every scale up campaign
- Cost efficient material supply for preclinical development needs
Talk to Our Experts
Capabilities
01
Designing Scalable Synthetic Pathways
We develop efficient and scalable synthetic routes by integrating process chemistry, analytical sciences, and engineering expertise from the earliest stages of development.
02
Accelerating Route Innovation Through AI
Advanced AI-driven retrosynthetic analysis and digital optimization help identify practical, cost-effective, and manufacturing-ready pathways for complex molecules.
03
Building Robust Manufacturing Processes
Through process optimization, impurity control, and operational understanding, we create reproducible processes that support successful scale-up and commercialization.
04
Delivering Regulatory-Ready Analytical Insights
Our analytical teams generate reliable characterization, impurity, stability, and quality data that support development decisions and global regulatory submissions.
05
Optimizing Solid-State Performance
We apply material science expertise to control polymorphism, particle attributes, and solid-state behavior that influence stability, manufacturability, and product performance.
06
Engineering Safer Paths to Scale
By integrating safety evaluations and engineering principles early, we enable reliable scale-up while minimizing operational and manufacturing risks.
07
Bridging Development and Clinical Readiness
Our pre-GMP scale-up capabilities help transition molecules from laboratory development to kilogram-scale production with speed, confidence, and efficiency.
Frequently asked questions
We’re here to help with any questions you have about our plans, supported features, and how our model works.
What are the key stages involved in developing an active pharmaceutical ingredient?
The journey from molecule to market involves route selection, process optimization, analytical method development, impurity characterization, material science studies, scale-up, and manufacturing readiness. Each stage plays a critical role in ensuring quality, scalability, and regulatory compliance.
How can development risks be reduced before manufacturing scale-up?
Early evaluation of process safety, impurity formation, critical process parameters, and solid-state properties helps identify potential challenges before large-scale manufacturing. This proactive approach improves reproducibility and minimizes costly development delays.
Why is synthetic route selection important for long-term commercial success?
The choice of synthetic route directly impacts manufacturing efficiency, cost, yield, sustainability, and scalability. Selecting the right pathway early helps create a stronger foundation for clinical supply, regulatory approval, and commercial production.
How do analytical and material science capabilities support pharmaceutical development?
Analytical and material science studies provide critical insights into product quality, stability, impurity control, polymorphism, particle characteristics, and manufacturability. These capabilities help ensure consistent performance throughout the product lifecycle.
How does PI Health Sciences accelerate the transition from development to manufacturing?
PI Health Sciences combines route scouting, process development, analytical sciences, process safety, and scale-up expertise within an integrated framework. This connected approach enables faster decision-making, reduced technical risk, and a smoother progression toward clinical and commercial manufacturing.
Contact Us
Connect with PI Health Sciences to advance your discovery chemistry services, from hit identification and hit-to-lead optimization to high-quality lead generation grounded in scientific rigor.